3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxopyridin-1-yl]-4-chloro-N-methylbenzamide | 1315271-39-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxopyridin-1-yl]-4-chloro-N-methylbenzamide
• CAS: 1315271-39-6
• 化学式: C₂₁H₁₆BrClF₂N₂O₃
• 分子量: 497.723
• InChiKey: WMGLBPVBWOFKHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-氨基-4-氯苯甲酸甲酯 在 溴 、 potassium carbonate 、 1-羟基苯并三唑 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 邻二氯苯 为溶剂， 反应 0.33h， 生成 3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxopyridin-1-yl]-4-chloro-N-methylbenzamide
  参考文献：
  名称：

  Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase

  摘要：

  The synthesis and SAR studies of a novel N-aryl pyridinone class of p38 kinase inhibitors are described. Systematic structural modifications to the HTS lead, 5, led to the identification of (-)-4a as a clinical candidate for the treatment of inflammatory diseases. Additionally, the chiral synthesis and properties of (-)-4a are described. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.121

文献信息

• Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase
  作者：Shaun R. Selness、Rajesh V. Devraj、Balekudru Devadas、John K. Walker、Terri L. Boehm、Richard C. Durley、Huey Shieh、Li Xing、Paul V. Rucker、Kevin D. Jerome、Alan G. Benson、Laura D. Marrufo、Heather M. Madsen、Jeff Hitchcock、Tom J. Owen、Lance Christie、Michele A. Promo、Brian S. Hickory、Edgardo Alvira、Win Naing、Radhika Blevis-Bal、Dean Messing、Jerry Yang、Michael K. Mao、Gopi Yalamanchili、Richard Vonder Embse、Jeffrey Hirsch、Matthew Saabye、Sheri Bonar、Elizabeth Webb、Gary Anderson、Joseph B. Monahan

  DOI：10.1016/j.bmcl.2011.04.121

  日期：2011.7

  The synthesis and SAR studies of a novel N-aryl pyridinone class of p38 kinase inhibitors are described. Systematic structural modifications to the HTS lead, 5, led to the identification of (-)-4a as a clinical candidate for the treatment of inflammatory diseases. Additionally, the chiral synthesis and properties of (-)-4a are described. (C) 2011 Elsevier Ltd. All rights reserved.